News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Kalkine Media Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
S&CO Inc. has acquired a new stake in AstraZeneca Plc, purchasing 37,990 shares valued at approximately $7.1 million during the second quarter. Institutional investors now collectively own 20.35% of AstraZeneca's stock. Analysts maintain a "Moderate Buy" rating for AstraZeneca, with an average price target …
Citizens, Inc. President and CEO Jon Stenberg recently purchased 12,000 shares of the company's Class A Common Stock for $43,795, reflecting increased executive ownership. This transaction occurred on August 11, 2026, with shares bought at $3.6496 each, near its 52-week low. InvestingPro analysis suggests …
Wall Street Zen upgraded Citizens & Northern (NASDAQ:CZNC) to a "strong-buy" rating. This follows other upgrades from Weiss Ratings and Zacks Research, although the overall analyst consensus remains "Hold" with a $23.50 target price. The company recently reported strong quarterly earnings of $0.79 per …
Citizens & Northern (NASDAQ:CZNC) stock recently surpassed its 200-day moving average, trading as high as $26.25, significantly above its long-term average of $22.76. Despite improved analyst sentiment and recent upgrades, the consensus rating remains "Hold" with a target price below the current share price. …
Braidwell LP and affiliated reporting persons have disclosed a beneficial ownership of 460,753 shares of Surrozen, Inc. common stock, representing approximately 3.9% of the class. This holding includes 390,753 directly owned shares and 70,000 shares acquirable through warrants within 60 days. The filing, an …
Boxer Capital Management, along with its affiliated entities and Aaron Davis, has disclosed an 8.9% beneficial ownership stake in Surrozen, Inc. (SRZN) through an amended Schedule 13G filing. The group beneficially owns 1,039,017 shares of common stock, representing 8.9% of the 11,610,371 shares outstanding …
Zenas BioPharma reported widening losses in Q2 2026, with revenue dropping significantly year-over-year and net loss reaching US$111,460,000. These financial results were accompanied by leadership changes, including the CFO transitioning to a Strategic Advisor role and a new board appointment. The company's investment narrative …
The article provides a detailed analysis of Surrozen Inc. (NASDAQ: SRZN) stock, highlighting strong sentiment across all horizons and an exceptional 86.7:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along …
StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have collectively reported a beneficial ownership of 5.0% in Surrozen, Inc. (SRZN). This stake includes 273,140 shares of common stock and 329,658 shares issuable upon exercise of Series A, B, and E warrants, …
Zentek Ltd. reported a net loss of $2,043,675 for Q1 2026, with no net sales. Despite the loss, the company significantly improved its liquidity, raising cash and cash equivalents to $16.6 million from $1.3 million, primarily through a private placement and ATM share sales. …
Latham & Watkins LLP advised Zentalis Pharmaceuticals, Inc. in its recent underwritten public offering, which is expected to generate approximately US$80.5 million in gross proceeds. The offering involved 23,000,000 shares of common stock at US$3.50 per share, with an option for underwriters to purchase …
DA Davidson has reiterated a Buy rating and an $85.00 price target for Citizens Financial Group (NYSE:CFG), citing strong growth prospects. The firm projects peer-leading EPS growth for Citizens Financial this year and next, supported by upward earnings revisions from analysts and various organic …
Manulife Financial Corporation, through its investment subsidiaries Manulife Investment Management (US) LLC and Manulife Investment Management Limited, has filed an amended Schedule 13G/A disclosing a beneficial ownership of less than 5% in Citizens Community Bancorp Inc. Manulife Investment Management (US) LLC holds 4.96% of …
Guggenheim reaffirmed its "buy" rating for Zenas BioPharma (ZBIO) with a $55 price target, despite the company reporting weaker-than-expected quarterly results, including an EPS loss of $1.77 and revenue of $1 million. Analyst sentiment for ZBIO remains generally positive with a "Moderate Buy" consensus …
Wedbush reiterated its "outperform" rating on Zenas BioPharma (NASDAQ:ZBIO) with a $45 price target, indicating a potential 54.11% upside. Despite this positive analyst sentiment, the company reported a significant miss on its quarterly earnings and revenue estimates. Other analysts have also adjusted their ratings, …
AstraZeneca PLC (AZN) shares fell 2.12% to £114.60 on Friday, underperforming the broader market as the FTSE 100 Index also declined. The company's stock closed significantly below its 52-week high, which was achieved earlier in the year.
Zentalis Pharmaceuticals has raised approximately USD 80.5 million through an equity offering to fund the late-stage development and pre-commercial activities for its oral WEE1 inhibitor, azenosertib. The drug is being evaluated for Cyclin E1-positive platinum-resistant ovarian cancer, with Phase II data expected by year-end …
Zentalis Pharmaceuticals (ZNTL [https://seekingalpha.com/symbol/ZNTL]) announced the pricing of an underwritten public offering [https://seekingalpha.com/pr/20619418-zentalis-pharmaceuticals-announces-pricing-of-underwritten-public-offering] of 23M shares of its common stock at a public offering price of $3.50 per share. Gross proceeds from the offering are expected to be approximately $80.5M before deducting underwriting discounts, …
(RTTNews) - Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage oncology company, priced a public offering of 23 million shares at $3.50 per share. The total gross proceeds from the offering are expected to be $80.5 million, and the company plans to use the net proceeds …
Search by ticker symbol or company name and select a result to open its chart.